Lamotrigine versus Valproic Acid as First‐line Monotherapy in Newly Diagnosed Typical Absence Seizures: An Open‐label, Randomized, Parallel‐group Study
- 24 August 2004
- Vol. 45 (9) , 1049-1053
- https://doi.org/10.1111/j.0013-9580.2004.40903.x
Abstract
Summary: Purpose:To compare the efficacy of lamotrigine (LTG) and valproic acid (VPA) in newly diagnosed children and adolescents with typical absence seizures.Methods:A randomized,open‐label parallel‐group design was used. After undergoing an awake video‐EEG recording, which included one to two trials of 3 min of hyperventilation and intermittent photic stimulation, eligible patients were randomized to receive LTG or VPA. LTG was initiated at a daily dose of 0.5 mg/kg for 2 weeks in two divided doses, followed by 1.0 mg/kg/day for an additional 2 weeks. Thereafter, doses were increased in 1‐mg/kg/day increments every 5 days until seizures were controlled, intolerable adverse effects occurred, or a maximum dose of 12 mg/kg/day had been reached. VPA was equally uptitrated according to clinical response, starting at 10 mg/kg and increasing by 5 mg/kg/24 h every 3 days, if required, to a maximum of 30 mg/kg/day in three divided doses. Patients were seen in the clinic every month for ≤12 months.The primary efficacy end point at each visit was seizure freedom, defined as lack of clinically observed seizures since the previous visit and lack of electroclinical seizures during ambulatory 24‐h EEG testing and a video‐EEG session with hyperventilation.Results: Thirty‐eight children (17 boys, 21 girls), aged from 3 to 13 years (mean, 7.5 years), all newly diagnosed with childhood or juvenile typical absence seizures, were enrolled. After 1 month of treatment, 10 (52.6%) of 19 children taking VPA and one (5.3%) of 19 taking LTG were seizure free (p = 0.004). By the 3‐month follow‐up, 12 (63.1%) children taking VPA and seven (36.8%) taking LTG were controlled (p = 0.19). After 12 months, 13 children taking VPA (dose range, 20–30 mg/kg/day; mean serum level, 76.8 mg/L; range, 51.4–91 mg/L) and 10 taking LTG (dose range, 2–11 mg/kg/day; mean serum level, 8.1 mg/L; range, 1.1–18 mg/L) were seizure free (p = 0.51). Side effects were mostly mild and transient and were recorded in two (10.6%) children treated with VPA and in six (31.8%) treated with LTG.Conclusions:Both VPA and LTG can be efficacious against absence seizures, although VPA shows a much faster onset of action, at least in part because of its shorter titration schedule.Keywords
This publication has 22 references indexed in Scilit:
- Lamotrigine as an add-on drug in typical absence seizuresActa Neurologica Scandinavica, 2009
- Treatment of Typical Absence Seizures and Related Epileptic SyndromesPediatric Drugs, 2001
- Disabling Erratic Myoclonus during Lamotrigine Therapy with High Serum Level–Report of Two CasesClinical Neuropharmacology, 2000
- Lamotrigine in Treatment of 120 Children with EpilepsyEpilepsia, 1994
- Valproic AcidDrugs, 1994
- Valproate in the Treatment of Absence Epilepsy in Children: A Study of Dose‐Response RelationshipsEpilepsia, 1988
- Evaluation of Treatment in Typical Absence Seizures: The Roles of Long‐term EEG Monitoring and EthosuximideActa Paediatrica, 1985
- Comparative Study of Ethosuximide and Sodium Valproate in the Treatment of Typical Absence Seizures (Petit Mal)Developmental Medicine and Child Neurology, 1982
- Proposal for Revised Clinical and Electroencephalographic Classification of Epileptic SeizuresEpilepsia, 1981
- Ethosuximide in the treatment of absence (petit mal) seizuresNeurology, 1975